Wuxi AppTec CoWUXIF 81 Receivables Turnover is 1.68 as of Mar. 2026. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $12.31 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks better than 62.56% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Wuxi AppTec Co's Revenue for the
three
months ended in Mar. 2026 was $1,804 Mil. Wuxi AppTec Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was $1,074 Mil.
Hence, Wuxi AppTec Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.68.
Wuxi AppTec Co (OTCPK:WUXIF) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Wuxi AppTec Co Receivables Turnover Related Terms
Wuxi AppTec Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuxi AppTec Co (WUXIF) has a Receivables Turnover of 1.68 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Wuxi AppTec Co and its competitors. According to the industry distribution chart, Wuxi AppTec Co ranks #76 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 37.4%.
Is Wuxi AppTec Co's Receivables Turnover too high?
Wuxi AppTec Co's current Receivables Turnover is 1.68. The Medical Diagnostics & Research industry median Receivables Turnover is 5.39. Wuxi AppTec Co's value of 1.68 is 68.8% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #76 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #76 out of 203 companies for Receivables Turnover. This puts Wuxi AppTec Co in the upper half of its industry. The industry median Receivables Turnover is 5.39. Wuxi AppTec Co's value of 1.68 is 68.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.39, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Receivables Turnover of 1.68 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Receivables Turnover is 1.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $12.31, compared to a current price of $20.58 — trading 67.1% above its estimated fair value. The current Receivables Turnover is 1.68 and 68.8% below the Medical Diagnostics & Research industry median of 5.39. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Receivables Turnover is 1.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $20.58 is trading 67.1% above its estimated GF Value™ of $12.31.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Receivables Turnover: 1.68
GF Value™: $12.31 vs. price of $20.58 (67.1% above fair value)
Industry Position: 68.8% below the Medical Diagnostics & Research median (#76 of 203)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
